[Acute psychoses and mood disorders in Parkinson disease. Role of antiparkinson therapy].
L-DOPA has progressively replaced atropinic substances in the treatment of the Parkinson's disease but its superiority is not evident in all domains. The same as these substances, it can occasion a secondary psychical pathology essentially presented by affective disorders and psychotic phenomena. The proposed study lays on the comparison between two parkinsonian groups, one undergoing a dopaminergic treatment the other one not. The hallucinary and confusing properties and to a lesser degree the depressive properties of L-DOPA are correlated to risk factors amongst which the average advanced age of the patients has the greatest place.
D000208:Acute Disease; D000341:Affective Disorders, Psychotic / Q000139:chemically induced*; D000367:Age Factors; D000368:Aged; D005260:Female; D006801:Humans; D007980:Levodopa / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000188:drug therapy*; D011605:Psychoses, Substance-Induced / Q000209:etiology*; D012306:Risk; D012737:Sex Factors; D013577:Syndrome; D013997:Time Factors
D007980:Levodopa
Psychoses aiguës et troubles de l'humeur dans la maladie de Parkinson. Le rôle des traitements anti-parkinsoniens.